What are NCCN recommendations for treatment of refractory or relapsed Hodgkin lymphoma (Hodgkin disease)?

Updated: Sep 12, 2018
  • Author: Bradley W Lash, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

Both the NCCN and ESMO guidelines recommend high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) for refractory or relapsed disease. The selection of second-line chemotherapy is determined by comparison with the agents previously used. [4, 5] Brentuximab vedotin is recommended for patients who have a failure of autologous stem cell transplantation or failure of at least two prior multi-agent chemotherapy regimens. [4, 5]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!